Mark Smolkin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10784295/publications.pdf

Version: 2024-02-01

1163117 1474206 14 482 8 9 citations h-index g-index papers 14 14 14 691 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Predictors of early, recurrent, and intractable seizures in low-grade glioma. Neuro-Oncology Practice, 2021, 8, 40-47.	1.6	9
2	Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist., 2021, 9, e002214.		11
3	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
4	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). , 2021, 9, e000934.		14
5	Risk of Venous Thromboembolism in Grade II–IV Gliomas as a Function of Molecular Subtype. Neurology, 2021, 96, e1063-e1069.	1.1	21
6	PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. Human Pathology, 2018, 81, 184-191.	2.0	16
7	A Novel Form of Breast Intraoperative Radiation Therapy With CT-Guided High-Dose-Rate Brachytherapy: Results of a Prospective Phase 1 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, 46-54.	0.8	55
8	Novel Risk Factors for Predicting the Development of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Undergoing Induction and Re-Induction Chemotherapy. Blood, 2016, 128, 5165-5165.	1.4	0
9	Tubular carcinoma of the breast: Institutional and SEER database analysis supporting a unique classification. Breast Disease, 2015, 35, 103-111.	0.8	14
10	A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes., 2014, 2, 23.		21
11	Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. Journal of Clinical Oncology, 2008, 26, 4973-4980.	1.6	108
12	A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 420-430.	2.4	100
13	Immunity to Melanoma Antigens: From Selfâ€Tolerance to Immunotherapy. Advances in Immunology, 2006, 90, 243-295.	2.2	55
14	Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2. Journal of Immunotherapy, 2005, 28, 412-419.	2.4	38